| pubmed-article:10815886 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10815886 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10815886 | lifeskim:mentions | umls-concept:C0024501 | lld:lifeskim |
| pubmed-article:10815886 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:10815886 | lifeskim:mentions | umls-concept:C0123759 | lld:lifeskim |
| pubmed-article:10815886 | lifeskim:mentions | umls-concept:C0278678 | lld:lifeskim |
| pubmed-article:10815886 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:10815886 | lifeskim:mentions | umls-concept:C0085732 | lld:lifeskim |
| pubmed-article:10815886 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:10815886 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:10815886 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:10815886 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:10815886 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:10815886 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:10815886 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:10815886 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:10815886 | lifeskim:mentions | umls-concept:C0721534 | lld:lifeskim |
| pubmed-article:10815886 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:10815886 | pubmed:dateCreated | 2000-8-29 | lld:pubmed |
| pubmed-article:10815886 | pubmed:abstractText | The aim of this study was to examine the tolerability, antitumor activity, and biological effects of a new schedule of i.v. recombinant human interleukin 12 (rhIL-12). Twenty-eight patients were enrolled in a Phase I trial in which rhIL-12 was administered twice weekly as an i.v. bolus for 6 weeks. Stable or responding patients were eligible to receive additional 6-week cycles until there was no evidence of disease or until tumor progression. Patient cohorts were treated with escalating doses of rhIL-12 (30-700 ng/kg). The maximum tolerated dose (MTD) was 500 ng/kg, with dose-limiting toxicities consisting of elevated hepatic transaminases and cytopenias. At the MTD (n = 14), there was one partial response occurring after 6 cycles of rhIL-12 in a patient with renal cell cancer. Two additional renal cell cancer patients treated at the MTD had prolonged disease stabilization, with one of these exhibiting tumor regression after 8 cycles of rhIL-12. IFN-gamma, IL-15, and IL-18 were induced in patients treated with rhIL-12. Whereas IFN-gamma and IL-15 induction were attenuated midway through the first cycle in patients with disease progression, those patients with tumor regression or prolonged disease stabilization were able to maintain IFN-gamma, IL-15, and IL-18 induction. The down-modulation of IFN-gamma induction during rhIL-12 treatment did not relate to IL-10 production or alterations in rhIL-12 bioavailability but was associated with an acquired defect in lymphocyte IFN-gamma production in response to IL-12, IL-2, or IL-15. This defect could be partially overcome in vitro through combined stimulation with IL-12 plus IL-2. These findings show that the chronic administration of twice-weekly i.v. rhIL-12 is well-tolerated, stimulates the production of IL-12 costimulatory cytokines and IFN-gamma, and can induce delayed tumor regression. Strategies aimed at maintaining IFN-gamma induction, such as the addition of IL-2, may further augment the response rate to this schedule of rhIL-12. | lld:pubmed |
| pubmed-article:10815886 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10815886 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10815886 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10815886 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10815886 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10815886 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10815886 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10815886 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10815886 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10815886 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10815886 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10815886 | pubmed:month | May | lld:pubmed |
| pubmed-article:10815886 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:10815886 | pubmed:author | pubmed-author:ClancyMM | lld:pubmed |
| pubmed-article:10815886 | pubmed:author | pubmed-author:MierJ WJW | lld:pubmed |
| pubmed-article:10815886 | pubmed:author | pubmed-author:AtkinsM BMB | lld:pubmed |
| pubmed-article:10815886 | pubmed:author | pubmed-author:McDermottD... | lld:pubmed |
| pubmed-article:10815886 | pubmed:author | pubmed-author:GollobJ AJA | lld:pubmed |
| pubmed-article:10815886 | pubmed:author | pubmed-author:ClancyDD | lld:pubmed |
| pubmed-article:10815886 | pubmed:author | pubmed-author:VeenstraKK | lld:pubmed |
| pubmed-article:10815886 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10815886 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:10815886 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10815886 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10815886 | pubmed:pagination | 1678-92 | lld:pubmed |
| pubmed-article:10815886 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:meshHeading | pubmed-meshheading:10815886... | lld:pubmed |
| pubmed-article:10815886 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10815886 | pubmed:articleTitle | Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. | lld:pubmed |
| pubmed-article:10815886 | pubmed:affiliation | Beth Israel Deaconess Medical Center, Division of Hematology/Oncology, Boston, Massachusetts 02215, USA. | lld:pubmed |
| pubmed-article:10815886 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10815886 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10815886 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:10815886 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:10815886 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10815886 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10815886 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10815886 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10815886 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10815886 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10815886 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10815886 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10815886 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10815886 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10815886 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10815886 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10815886 | lld:pubmed |
